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Pigment epithelium-derived factor
mediates retinal ganglion cell
neuroprotection by suppression
of caspase-2
Vasanthy Vigneswara1 and Zubair Ahmed1
Abstract
Retinal ganglion cells (RGCs) undergo rapid cell death by apoptosis after injury but can be rescued by suppression of
caspase-2 (CASP2) using an siRNA to CASP2 (siCASP2). Pigment epithelium-derived factor (PEDF), has neuroprotective
and anti-angiogenic functions and protects RGC from death. The purpose of this study was to investigate if
suppression of CASP2 is a possible mechanism of neuroprotection by PEDF in RGC. Adult rat retinal cells were treated
in vitro with sub-optimal and optimal concentrations of siCASP2 and PEDF and levels of CASP2 mRNA and RGC
survival were then quantiﬁed. Optic nerve crush (ONC) injury followed by intravitreal injections of siCASP2 or PEDF and
eye drops of PEDF-34 were also used to determine CASP2 mRNA and protein reduction. Results showed that PEDF and
PEDF-34 signiﬁcantly suppressed CASP2 mRNA in culture, by 1.85- and 3.04-fold, respectively, and increased RGC
survival by 63.2 ± 3.8% and 81.9 ± 6.6%, respectively compared to cells grown in Neurobasal-A alone. RGC survival was
signiﬁcantly reduced in glial proliferation inhibited and puriﬁed RGC cultures suggesting that some of the effects of
PEDF were glia-mediated. In addition, intravitreal injection of PEDF and eye drops of PEDF-34 after ONC also
suppressed CASP2 mRNA levels by 1.82- and 3.89-fold and cleaved caspase-2 (C-CASP2) protein levels by 4.98- and
8.93-fold compared to ONC+ PBS vehicle groups, respectively, without affecting other executioner caspases.
Treatment of retinal cultures with PEDF and PEDF-34 promoted the secretion of neurotrophic factors (NTF) into the
culture media, of which brain-derived neurotrophic factor (BDNF) caused the greatest reduction in CASP2 mRNA and
C-CASP2 protein. The neuroprotective effects of PEDF were blocked by a polyclonal antibody and PEDF suppressed
key elements in the apoptotic pathway. In conclusion, this study shows that some of the RGC neuroprotective effects
of PEDF is regulated through suppression of CASP2 and downstream apoptotic signalling molecules.
Introduction
Optic nerve crush (ONC) leads to the rapid death of
retinal ganglion cells (RGCs) by apoptosis, attributed to
the loss of trophic support. However, RGC can be pro-
tected from death by a variety of neurotrophic factors
(NTFs) including brain-derived neurotrophic factor,
ciliary neurotrophic factor and glial cell line-derived
neurotrophic factor1–4. Others and our recent work
have shown that pigment epithelium-derived factor
(PEDF), a 50 kDa neurotrophic factor belonging to the
serpin superfamily, is neuroprotective for a wide variety of
CNS neurons including RGC5–12. Furthermore, PEDF
promotes signiﬁcant RGC axon regeneration after ONC
and a neurotrophic fragment of PEDF and PEDF-34,
penetrates into the vitreous body and retina after topical
delivery and promotes signiﬁcant RGC survival and axon
regeneration12.
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Caspases are a family of cysteine-rich proteases that are
expressed as pro-caspases and activated either by
proximity-induced dimerisation or proteolytic cleavage
and orchestrate apoptosis during development and in the
adult13. Once activated, caspases target regulatory pro-
teins involved in DNA replication, DNA repair, cell sur-
vival signalling and the cytoskeletal reorganisation14–19.
Caspase-2 (CASP2) is the most highly conserved of
the caspases and is speciﬁcally activated in RGC after
ONC20–23. Inhibition of CASP2 with a stable modiﬁed
siRNA to CASP2 (siCASP2) promoted the survival
of >95% of RGC from death for up to 12 weeks after
ONC20–24. These studies demonstrate that CASP2 acti-
vation is required for RGC death.
CASP2 resembles other caspase in possessing a
long pro-domain containing a caspase recruitment
domain (CARD) sequence and is activated by proximity-
induced dimerisation which is facilitated by various
adaptor molecules13. For CASP2, the adapter protein
receptor interacting protein-associated interleukin-1β-
converting enzyme/CED-3 homologue 1 protein with a
death domain (RAIDD), interacts with CARD via its
death domain (DD) and activates CASP225. Later studies
showed that RAIDD can also interact with p53-
inducible protein with a death domain (PIDD) via the
DD and hence forming the PIDDosome, composed of
PIDD, RAIDD, and C-CASP2 as the activation complex
for CASP226. More recently, RAIDD and not PIDD was
shown to be required for CASP2-dependent hippo-
campal neuronal death, activated by either NGF with-
drawal or Aβ1-42 peptide treatment
27. Moreover,
activation of CASP2 promoted the induction of down-
stream Bcl-2-interacting mediator of death (Bim) and
that this was mediated by CASP2-dependent activation
of the transcription factor, c-Jun28.
In this study, we evaluated, in vitro and in vivo, the
levels of CASP2 expression in RGC after treatment with
PEDF and PEDF-34 to determine how PEDF and PEDF-
34 exerts its neuroprotective effect on RGC. We further
investigated whether PEDF treatment modulated RAIDD
or PIDD or downstream c-Jun and Bim in the pathway to
activation of CASP2 after ONC in RGC death.
Materials and methods
Experimental design: in vitro experiments
For all in vitro experiments, retinal cells were cultured
from 6–8-week-old adult female Sprague Dawley rats
(170–220 g)11 and experimental conditions for PEDF and
PEDF-34 treatment included retinal cells treated with: (1),
supplemented Neurobasal-A (NBA; supplemented with
B27 supplement and L-Glutamine; all from Invitrogen,
Paisley, UK) alone; and previously optimised doses of (2),
2.5 × 10–5µg/µL human PEDF (equivalent to 463 pM;
Phoenix Europe GmbH, Karlsruhe, Germany); (3), 5.4 pM
human PEDF-34 (amino acids 44–77 of the N-terminus of
human PEDF protein (PFFKVPVNKLAAAVSNFGY-
DLYRVRSSTSPTTNV) chemically synthesised by Vig-
neswara et al.11) and (4), 5.4 pM human PEDF-44 (amino
acids 78–101; Phoenix Europe GmbH)11,12.
For knockdown of CASP2 mRNA, retinal cells were
treated with: (1), NBA alone; (2), Lipofectamine 2000
alone (Lipofectamine); (3), pre-optimised non-speciﬁc
siGFP (50 nM); (4) pre-optimised siCNL, a control
scrambled version of siCASP2 (50 nM); and (5), varying
concentrations of siCASP2 (10–200 nM20).
All in vitro experiments described in this manuscript
were performed in triplicate wells and repeated on three
independent occasions (total n= 9 wells/treatment) by
an investigator masked to the treatment conditions.
Mixed adult retinal cultures
Mixed adult rat retinal cultures containing enriched
populations of RGC were prepared as described pre-
viously11. Brieﬂy, retinal cells were dissociated using a
Papain dissociation kit according to the manufacturer’s
instructions (Worthington Biochemicals, Lakewood, NJ,
USA). 125 × 103 retinal cells/well were plated in poly-D-
lysine and laminin pre-coated 8-well chamber
slides and cultured in NBA. Cells were cultured for
4 days (d) at 37oC and 5% CO2 before RNA extraction
for qRT-PCR or ﬁxation in 4% formaldehyde for
immunohistochemistry.
To limit glial cell proliferation, mixed retinal cultures
were treated with 30 µM 5-ﬂuro-2-deoxyuridine (5-FDU,
Sigma)29.
Puriﬁed adult RGC cultures
RGCs were puriﬁed from twenty 6–8-week-old adult
Sprague-Dawley rat retinae and puriﬁed by sequential
immunopanning, as described for postnatal rats30.
Brieﬂy, retinae were dissociated using neural tissue
dissociation kit containing papain and sequential pas-
saging through serological and ﬁre-polished Pasteur
pipettes according to the manufacturer’s instructions
(Miltenyi Biotec, Woking, UK). Two culture dishes were
used for depletion and were coated in anti-rabbit IgM
and goat anti-rabbit IgM followed by anti-rat CD90.1/
Thy1.1 antibody (Cat No. ab203022; Abcam, Cam-
bridge, UK). Cells were allowed to adhere to the ﬁrst
depletion plate and the non-adherent cells were sub-
jected to a further round of depletion before being
applied to the second selection plate. Cells adhering to
the second plate were washed, collected by trypsiniza-
tion and subsequent centrifugation before being plated
in 8-well chamber slides at a plating density of 10,000
RGC/well in supplemented NBA and incubated at 37oC
and 5% CO2. Cells were cultured for 4 days prior to
harvesting and total RNA extraction for qRT-PCR.
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Knockdown of CASP2
For the siCASP2 knockdown experiments in mixed
adult retinal cells, the optimal dose of siCASP2 to knock
down CASP2 mRNA was determined by qRT-PCR in a
preliminary experiment using pre-optimised CASP2 pri-
mers20. An initial dose–response curve with 5, 10, 20, 50,
100 and 200 nM of siCASP2 was used to determine that
the optimal dose of siCASP2 was 50 nM, which caused
95% knockdown of CASP2 mRNA. Controls for this
experiment included control cells incubated in NBA
alone, Lipofectamine 2000, pre-optimised non-speciﬁc
siGFP and siCNL20.
Other rat CASP2 siRNA sequences were pre-optimised
for CASP2 mRNA knockdown in retinal cultures prior to
use (data not shown) and included: 20 nM S1–5′-GCCA
UGCACUCCUGAGUUU-3′;28 20 nM S2 – CASP2 siRNA,
cat no. SC-72108 (Santa Cruz Biotechnology, San Diego,
CA, USA); and 10 nM S3 – CASP2 siRNA, cat no.
AM16708 (Assay ID 194613) (ThermoFisher Scientiﬁc,
Loughborough, UK), which gave maximum knockdown
efﬁciencies of 70% in mixed and puriﬁed retinal cultures.
Mixed retinal and puriﬁed adult rat RGC cultures were
treated with the optimised concentrations of siCASP2,
PEDF, PEDF-34 and PEDF-44 and appropriate controls as
described for mixed retinal cells above. All experiments
were performed in triplicate and repeated on three inde-
pendent occasions.
Immunocytochemistry of retinal cultures
Fixed cells were washed in several changes of phosphate
buffered saline (PBS) before permeablisation and blocking
in PBS containing 3% bovine serum albumin (BSA) and
0.1% Triton X-100 (both from Sigma, Poole, UK). Cells
were then incubated with monoclonal anti-βIII-tubulin
antibody (Cat No. T8660; 1:200 dilution; Sigma) for 1 h at
room temperature (RT) and used to localise RGC and
their neurites. Cells were then washed in several changes
of PBS and incubated with Alexa 488 anti-mouse IgG (Cat
No. A-11001; 1:400 dilution; Invitrogen) for 1 h at RT,
washed in several changes of PBS and mounted using
Vectashield containing DAPI (Vector Laboratories,
Peterborough, UK). Slides were then anonymised by a
second investigator and viewed using a Zeiss epi-
ﬂuorescent microscope equipped with an AxioCam HRc
and Axiovision Image capture software (all from Zeiss,
Hertfordshire, UK). Immunocytochemistry included
controls with primary antibody omitted, that were used to
set background levels of nonspeciﬁc staining (not shown)
prior to image capture.
Quantiﬁcation of RGC survival
Each well of the chamber slides were divided into nine
quadrants and images captured randomly from each
quadrant. RGC survival was then determined by counting
the number of surviving βIII-tubulin+ RGC in each of the
9 quadrants/well and total RGC survival determined
through multiplying by the area of each chamber.
Quantiﬁcation of non-neuronal cells
Non-neuronal cells were counted in 8-well chamber
slides as described by us previously31. Brieﬂy, each 8-well
chamber slide was partitioned into nine quadrants and
DAPI counterstained cells (all cells) were subtracted from
those stained with βIII-tubulin (RGC) to give an estimate
of the number of neuronal cells versus non-neuronal cells.
Assessment of neurotrophic factor levels in culture
medium by ELISA
Mixed adult rat retinal cultures containing enriched
populations of RGC were prepared as described in 2.2.
above. Retinal cells were treated with 5.4 pM human
PEDF-34 (Peprotech) in NBA for 5 h before carefully
washing cells in 3 changes of PBS to remove all traces of
PEDF-34. NBA was then replaced into each well and cells
incubated at 37oC and 5% CO2 for 3 days. To limit glial
cell proliferation, cultures were also treated with 30 µM 5-
FDU (Sigma) for the duration of the experiment29. Cul-
ture media was collected, centrifuged to remove cell
debris and subjected to ELISA to detect NTFs: brain-
derived neurotrophic factor (BDNF); ciliary neurotrophic
factor (CNTF); glial cell line-derived factor (GDNF); nerve
growth factor (NGF) and neurotrophin-3 (NT-3) (all from
Abcam), according to the manufacturer’s instructions.
PEDF antibody blocking experiments
In a preliminary dose response experiment, the optimal
concentration of goat polyclonal anti-rat PEDF antibody
(Cat No. AF1177; R&D Systems Europe) to antagonise the
effects of pre-optimised PEDF and PEDF-34 on RGC
survival in vitro was determined11,12. PEDF (563 pM) and
PEDF-34 (5.4 pM) was mixed with varying amounts of
PEDF antibody ranging from 1 to 50 µg/ml dissolved in
PBS for 2 h at RT before adding onto cultured retinal cells
and incubated at 37 oC and 5% CO2 for 3 days. Control
wells included PEDF and PEDF-34 that were pre-treated
with an equal volume of PBS (vehicle) or an equal con-
centration of normal rat IgG control (non-speciﬁc anti-
body control). Cells were then subjected to
immunocytochemistry for βIII-tubulin and determination
of βIII-tubulin+ RGC survival as described above. We
determined that 15 µg/ml was sufﬁcient to completely
block the neuroprotective effect of PEDF and PEDF-34
whilst neither vehicle nor control rat IgG-treated wells
affected RGC survival (not shown).
In further experiments, mixed adult retinal cultures
were subjected to pre-optimised PEDF blocking anti-
bodies and used to determine changes in CASP2 mRNA
and protein and the neuroprotective effects on RGC
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survival determined in the presence or absence of PEDF
blocking antibody.
Experimental Design: in vivo experiments
All in vivo tissue samples used for western blot and
immunohistochemistry were derived from samples col-
lected as part of previously published studies11,12,20,22,23.
Animal procedures were licenced by the UK Home
Ofﬁce and approved by the University of Birmingham’s
Ethical Review Board. All animal surgeries were carried
out in strict accordance to the guidelines of the UK
Animals Scientiﬁc Procedures Act, 1986 and the Revised
European Directive 1010/63/EU and conformed to the
guidelines and recommendation of the use of animals by
the Federation of the European Laboratory Animal
Science Associations. Experiments also conformed to
the ARVO statement for use of animals in research,
except that bilateral optic nerve crushes are a condition
of our licence, imposed by the UK Home Ofﬁce. This is
viewed as ‘reduction’ in keeping with the 3 R’s principle,
since rats do not rely on sight as a primary sense and
none of the normal behaviours are altered as a result.
Adult female Sprague-Dawley rats (6–8-week-old,
170–220 g) were used for all in vivo experiments and
randomly assigned to each treatment group presented in
this study comprising 6 eyes (n= 6 retinae/3 rats) and
repeated on three separate occasions (total= 18 eyes
(n= 18 retinae/9 rats)/treatment group)11,12. Brieﬂy,
optic nerves were crushed bilaterally 2 mm from the
globe in anaesthetised rats as described previously32.
PEDF or PEDF-34 were either injected intravitreally
every 8 days after optic nerve crush (ONC) until the end
of the experiment or given as topical eye drops every
day, respectively, based on previously optimised dose
frequency/concentration studies11,12.
Animals were allowed to survive for up to 28d prior to
killing by CO2 overdose and retinae were either snap
frozen in liquid nitrogen (for RNA (n= 9 rats (18 retinae)/
group from three independent repeats; 63 rats in total)
and total protein extraction (n= 9 rats (18 retinae)/group
from three independent repeats; 63 rats in total) for qRT-
PCR and Western blot) or whole eyes ﬁxed in 4% paraf-
ormaldehyde (n= 9 rats (18 retinae)/group from three
independent repeats; 27 rats in total (3 groups)) for
cryoprotection and immunohistochemistry. To determine
the effect of PEDF-34 eye drops over 21d on caspase-2
levels by qRT-PCR, RNA was extracted from 6 rats (12
retinae)/group from two independent repeats; a total of 54
rats. To determine changes in C-CASP2 levels over 3d by
western blot and RAIDD, PIDD, phospho-c-Jun, c-Jun
and Bim levels by western blot at 3d, 9 rats (18 retinae)/
group from three independent repeats were used to
extract total protein; a total of 54 rats. To analyse mRNA
and protein levels by qRT-PCR and western blot, each
independent repeat comprising 6 eyes (3 rats)/treatment
were pooled, treated and analysed separately prior to
averaging the data over the two or three independent
repeats to achieve the ﬁnal data presented in the ﬁgures of
this study. All rats were included in the study as there
were no unsuccessful ONC animals and no rats suffered
complications during surgery.
Preparation of PEDF, PEDF-34 and PEDF-44 for in vivo use
PEDF was dissolved in PBS and 1.88 nM ﬁnal con-
centrations in 5 μl were intravitreally injected into
appropriate eyes under anaesthesia and as previously pre-
optimised in vivo11.
Eye drops of PEDF-34/44 were prepared fresh daily in
0.9% saline and 1.88 nM ﬁnal concentrations in a volume
of 5 µl were applied topically as previously pre-optimised
in vivo12. Brieﬂy, animals were lightly anesthetised to
prevent blinking and 5 μl of PEDF was dropped onto the
surface of the eye and repeated daily for 28d.
Tissue preparation and sectioning
Fixed whole eyes were post-ﬁxed for 2 h in 4% paraf-
ormaldehyde, cryoprotected through a graded sucrose
solution, blocked up in OCT embedding compound
(Raymond A Lamb, Eastbourne, UK), cut at 15-μm-thick
using a cryostat (Brights Instruments, Huntingdon, UK)
and adhered onto charged slides prior to immunohis-
tochemistry, as described previously12.
Immunohistochemistry of retinal sections
Sections were washed in PBS, permeablised in 0.1%
Triton X-100 (Sigma) in PBS and nonspeciﬁc binding
blocked in 3% bovine serum albumin (BSA) in PBS for 30
min. Appropriate primary antibodies (Table 1) were
diluted in PBS containing 3% BSA and 0.05% Tween 20
and incubated overnight in a humidiﬁed chamber at 4oC.
Sections were then washed in PBS and incubated with
corresponding Alexa488 and Texas Red labelled anti-
mouse and anti-rabbit IgG, diluted in PBS containing BSA
and 0.05% Tween 20 and incubated in a humidiﬁed
chamber for 1 h at room temperature. Sections were then
washed in PBS and coverslips mounted using Vectashield
containing DAPI (Vector Laboratories), examined using
an Axioplan-2 epi-ﬂuorescent microscope and images
captured using an AxioCam HRc as described above.
Immunocytochemistry included controls with primary
antibody omitted, that were used to set background levels
of nonspeciﬁc staining (not shown) prior to image
capture.
RNA extraction and qRT-PCR
Total RNA from cells and eye tissues were extracted
using Trizol reagent (Invitrogen) according to the man-
ufacturer’s instructions, reverse transcribed into cDNA
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and the levels of rat CASP2 (5′-GGCGGAGGAGTTC
CACATTC-3′ (forward) and 5′-GTGCAGGGTCC
GAGGT-3′ (reverse)), RAIDD (Cat no. 4331182,
Rn0109149-m1, ThermoFisher), PIDD (Cat no. 4351372,
Rn01479823_g1, ThermoFisher), Bim (Cat no. 4331182,
Rn00674175_m1) mRNA was detected by qRT-PCR, as
described by us previously20. Brieﬂy, qPCR was performed
using a Bio-Rad iQ5 PCR detection system with SYBR
green PCR mastermix (Thermo Fisher Scientiﬁc, Paisley,
UK). Primer efﬁciency was tested using a 7-point standard
curve, and gene expression calculated using the 2−ΔΔCt
method and normalised to the expression of β-actin (5′-
ACCTTCTACAATGAGCTGCG-3′ (forward) and 5′-
CTGGAATGGCTACGTACATGG-3′ (reverse).
Protein extraction and western blot analysis
Protein extraction and western blot was performed
according to our previously published studies31. Brieﬂy,
retinal cultures in vitro or retinal tissue from in vivo
experiments were lysed with ice-cold lysis buffer and
lysates collected and clariﬁed by centrifugation. 20 μg of
total protein extract was resolved on 10% SDS gels,
transferred to polyvinylidine ﬂuoride membranes and
probed with relevant primary antibodies as detailed in
Table 1, followed by incubation with appropriate HRP-
labelled anti-rabbit or anti-mouse IgG (GE Healthcare,
Buckinghamshire, UK). Bands were detected using the
enhanced chemiluminescence kit (GE Healthcare). Mouse
anti β-actin primary antibody, followed by HRP-labelled
anti-mouse IgG (GE Healthcare) was used as a protein
loading control.
Densitometry
Western blots were scanned into Adobe Photoshop
(Adobe Systems Inc, San Jose, CA, USA) keeping all
scanning parameters the same between blots. The inte-
grated density of bands were then analysed using the
built-in-macros for gel analysis in ImageJ (NIH, USA,
http://imagej.nih.gov/ij) and means ± SEM were plotted in
Microsoft Excel (Microsoft Corporation, CA, USA)32.
Statistical analysis
Sample means were calculated for each variable and
analysed for signiﬁcance by one-way analysis of variance
Table 1 List of primary and secondary antibodies used for western blot (WB), immunohistochemistry (IHC) and
immunocytochemistry (ICC)
Antibody Source Cat No. Dilution
Primary antibodies
WB IHC/ICC
Goat anti-cleaved caspase-2 (p12) Santa Cruz Biotechnology, San Diego, CA, USA sc-623 1:200 1:200
Rabbit anti-cleaved caspase-3 Cell Signalling Technology, Danvers, MA, USA 9664 1:200
Rabbit anti-cleaved caspase-6 Cell Signalling Technology, Danvers, MA, USA 9761 1:200
Rabbit anti-cleaved caspase-7 Cell Signalling Technology, Danvers, MA, USA 8438 1:200
Rabbit anti-cleaved caspase-8 Cell Signalling Technology, Danvers, MA, USA 9496 1:200
Rabbit anti-RAIDD Abcam, Cambridge, UK ab76465 1:1000
Rabbit anti-PIDD Merck Millipore, Watford, UK MACB189 1:1000
Rabbit anti-Phospho-c-Jun(Ser63) Cell Signalling Technology, Danvers, MA, USA 2361 1:750
Rabbit anti-c-Jun Cell Signalling Technology, Danvers, MA, USA 9165 1:750
Rabbit anti-Bim Cell Signalling Technology, Danvers, MA, USA 2933 1:1000
Mouse anti-βIII tubulin Sigma, Poole, UK T8660 1:500
Mouse anti-β actin Sigma, Poole, UK A5441 1:400
Secondary antibodies
HRP-labelled anti-mouse IgG GE Healthcare, Buckingham, UK NA931 1:1000
HRP-labelled anti-rabbit IgG GE Healthcare, Buckingham, UK NA934 1:1000
HRP-labelled anti-goat IgG Santa Cruz Biotechnology, San Diego, CA, USA sc-2020 1:1000
Alexa594 anti-goat IgG Invitrogen, Poole, UK A-11058 1:400
Alexa488 anti-mouse IgG Invitrogen, Poole, UK A-11001 1:400
Alexa488 anti-rabbit IgG Invitrogen, Poole, UK A-21206 1:400
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(ANOVA) followed by post-hoc testing with Dunnett’s
method. Signiﬁcance level, α, was set at 5% and hence
differences were considered signiﬁcant if P < 0.05.
Results
Suppression of CASP2 by siCASP2 results in RGC
neuroprotection in vitro
In a preliminary experiment, we used siCASP2 to vali-
date CASP2 mRNA knockdown in isolated adult rat ret-
inal cultures containing RGC. In NBA-treated cultures,
CASP2 mRNA was 5.3 ± 0.4-fold, which did not change in
Lipofectamine, siGFP and siCNL-treated cultures
(Fig. 1a). However, increasing the concentration of
siCASP2 to 50 nM caused a dose-dependent decrease in
CASP2 mRNA when only 0.53 ± 0.1-fold mRNA
remained (Fig. 1a). Increasing the concentration of
siCASP2 beyond 50 nM did not further reduce the levels
of CASP2 mRNA. Western blot (Fig. 1b) and subsequent
densitometry (Fig. 1c) was used to verify C-CASP2 pro-
tein knockdown by siCASP2 and showed that in NBA and
siCNL-treated cultures high levels of C-CASP2 was acti-
vated whilst 20 and 50 nM siCASP2 signiﬁcantly reduced
C-CASP2 levels.
The percentage (%) of βIII-tubulin+ RGC in NBA,
Lipofectamine, siGFP and siCNL-treated cultures were
similar, showing that only 28 ± 5%, 27 ± 4% and 28 ± 4%
RGC survived for 3d in culture, respectively (Fig. 1d, e).
However, increasing the concentration of siCASP2 led to
a dose-dependent increase in the % of surviving βIII-
tubulin+ RGC, reaching a maximum of 95.6 ± 2.4% at 50
nM (Fig. 1d, e). Increasing the dose of siCASP2 above 50
nM led to a reduction in the % of βIII-tubulin+ RGC.
Taken together, these results demonstrate that 50 nM
siCASP2 optimally reduced CASP2 mRNA and protein
levels in cultured retinal cells and neuroprotects >95% of
cultured RGC.
PEDF suppresses CASP2 mRNA in cultured retinal cells
We showed previously that PEDF promoted signiﬁcant
RGC survival in vitro and in vivo and now speculated that
PEDF may promote RGC neuroprotection through sup-
pression of CASP2. Retinal cell cultures grown in NBA for
3d showed a 6.5 ± 0.58-fold increase in the levels of
CASP2 mRNA compared to that observed in freshly iso-
lated retinal cells (Fig. 2a). The rise in CASP2 mRNA
levels in NBA and NBA+ siCNL-treated cultures were
suppressed completely by 50 nM siCASP2 (7.64-fold
suppressed compared to NBA or NBA+ siCNL-treated
cultures), whilst PEDF and PEDF-34 also reduced the fold
change in CASP2 mRNA to 3.36 ± 0.44 and 2.15 ± 0.33,
respectively (Fig. 2a). These results equate to a signiﬁcant
1.93- and 3.02-fold reduction in CASP2 mRNA after
treatment with PEDF and PEDF-34, respectively, com-
pared to cells grown in NBA or NBA+ siCNL. PEDF-44,
however, was unable to suppress CASP2 mRNA com-
pared to NBA and NBA+ siCNL-treated controls
(Fig. 2a).
We conﬁrmed that suppression of CASP2 mRNA by
50 nM siCASP2 and PEDF/PEDF-34 was neuroprotective
to βIII-tubulin+ RGC. As a control for RGC neuropro-
tection, we compared neuroprotection offered by PEDF
and PEDF-34 to that offered by 50 nM siCASP2. In NBA
or NBA+ siCNL-treated cultures, only 20.5 ± 4.6% of
RGC survived for 3d (Fig. 2b). As expected, in all groups
treated with 50 nM siCASP2, 95.6 ± 3.2% of RGC were
protected from death, whilst PEDF and PEDF-34 pro-
moted the survival of 63.2 ± 4.2% and 81.0 ± 6.9% of RGC
from death, respectively. PEDF-44 had a smaller positive
effect on RGC survival than either PEDF or PEDF-34,
neuroprotecting 42.7 ± 8.3% of RGC. These results sug-
gest that treatment of retinal cells with PEDF and PEDF-
34 signiﬁcantly suppress CASP2 mRNA levels and that
RGC neuroprotection is proportional to suppressed
CASP2 levels.
To test whether suppression of CASP2 mRNA observed
with PEDF is additive when combined with suboptimal
concentrations of siCASP2, we treated retinal cells with 5,
10 and 20 nM siCASP2, with or without PEDF. The
combination of suboptimal concentrations of siCASP2
(i.e. 5, 10 and 20 nM) along with PEDF and PEDF-34
suppressed CASP2 mRNA levels in a dose-dependent
manner, with PEDF-34 causing the greatest decrease
(Fig. 2c). The level of suppression of CASP2 mRNA cor-
related directly with RGC neuroprotection, with NBA+
20 nM siCASP2+ PEDF-34 showing nearly 95% RGC
neuroprotection (Fig. 2d). In contrast, PEDF-44 had no
additive effects on CASP2 mRNA suppression (Fig. 2c)
nor RGC neuroprotection (Fig. 2d) when combined with
suboptimal siCASP2 concentrations.
Other preoptimized rat CASP2 siRNA sequence (S1-3),
despite having different abilities to knock down CASP2
mRNA (Supplementary Fig. 1A) and promote RGC sur-
vival (Supplementary Fig. 1B) on their own were also
similarly additive in the presence of PEDF and PEDF-34 as
siCASP2.
Taken together, these results suggest that treatment of
retinal cells with PEDF and PEDF-34 signiﬁcantly sup-
press CASP2 mRNA levels and that RGC neuroprotection
is proportional to suppressed CASP2 levels.
PEDF suppresses CASP2 mRNA in vivo
CASP2 mRNA levels rose to 8.63 ± 0.41-fold at 7d after
ONC+ PBS treatment compared to that observed in
intact controls (Fig. 3a). Intravitreal injection of siCASP2
completely suppressed the ONC-induced rise in CASP2
mRNA such that levels were 1.24 ± 0.21 compared to
intact controls. Intravitreal injection of PEDF and eye
drops of PEDF-34 both signiﬁcantly reduced ONC-
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induced CASP2 mRNA such that CASP2 mRNA levels
were 4.73 ± 0.33 and 2.22 ± 0.23 compared to intact con-
trols, a reduction of 1.82- and 3.89-fold compared to ONC
alone. PEDF-44 had little or no effect on CASP2 mRNA
levels. In addition, intravitreal injection of control siCNL
had no effect on ONC-induced induction of CASP2
mRNA. These changes were also conﬁrmed by western
blot analysis for cleaved caspase-2 (C-CASP2) with
antibodies speciﬁc for the p12 fragment showing that
ONC-induced C-CASP2 protein levels were almost
completely suppressed by siCASP2 and signiﬁcantly
reduced by PEDF and PEDF-34 (Fig. 3b, c). PEDF-44 and
control siCNL had no effect on C-CASP2 levels compared
to ONC+ PBS-treated animals.
In addition, despite signiﬁcant activation of cleaved
caspase-3 (C-CASP3) and cleaved caspase-6 (C-CASP6)
Fig. 1 Validation of CASP2 knockdown by siCASP2 in vitro. a Fold change in CASP2 mRNA in siCASP2-treated retinal cells showing a dose-
dependent decrease in CASP2, whilst Lipofectamine 2000 (Lipofectamine), non-speciﬁc siGFP and control scrambled siRNA to CASP2, siCNL, have no
effect of CASP2 mRNA levels (n= 9 wells/treatment). b, c Western blot and subsequent densitometry to show signiﬁcant reduction in C-CASP2
protein with 20 and 50 nM siCASP2 (n= 9 wells/treatment). d Quantiﬁcation to show that knockdown of siCASP2 with an optimal dose of 50 nM
promotes signiﬁcant RGC neuroprotection in culture (n= 9 wells/treatment). e Representative images of selected groups to show morphology of
βIII-tubulin+ RGC. Scale bar in e= 20 µm
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after ONC, levels of these and other executioner caspases
including cleaved caspase-7 (C-CASP7) and cleaved
caspase-8 (C-CASP8) all remained unchanged after
siCASP2 and PEDF/PEDF-34 treatment (Supplementary
Fig. 2). Taken together, these results suggest that only
CASP2 mRNA and its active levels are signiﬁcantly sup-
pressed in vivo by siCASP2 and PEDF treatment.
PEDF-34 eye-drops also suppressed CASP2 levels in vivo
ONC+ saline induced upregulation of CASP2 mRNA
within 1d to 6.44 ± 0.38-fold over intact controls, peaking
at 3d to 7.01 ± 0.54-fold and remained high for up to 7d.
At 14 and 21d after ONC+ saline, CASP2 mRNA
remained at 2.33 ± 0.33-fold above that of intact controls
(Fig. 4a). However, PEDF-34 eye-drops suppressed CASP2
Fig. 2 PEDF suppresses CASP2 and promotes neuroprotection in culture. a Fold change in CASP2 mRNA relative to β-actin reference gene in
retinal cells freshly isolated and after 3d exposure to NBA, siCNL, 50 nM siCASP2 and PEDF/PEDF-34/PEDF-44. b % of surviving βIII-tubulin+ RGC after
3d in culture in NBA, and after treatment with siCNL, 50 nM siCASP2 and PEDF/PEDF-34/PEDF-44. c Fold change in CASP2 mRNA relative to β-actin
reference gene in retinal cells freshly isolated and after 3d exposure to suboptimal doses of siCASP2 (5–20 nM) with and without PEDF/PEDF-34/
PEDF-44. d % of surviving βIII-tubulin+ RGC after 3d in culture in with suboptimal concentrations of siCASP2 (5–20 nM) with and without PEDF/PEDF-
34/PEDF-44 (n= 9 wells/treatment)
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mRNA 1d after ONC to 3.47 ± 0.37-fold, reducing further
at 3d when CASP2 mRNA levels were 1.11 ± 0.13-fold
above that observed in intact controls. No further
reduction of CASP2 mRNA was observed after 3d, sta-
bilising at approximately 7-fold less than that observed
after ONC+ saline treatment.
CASP2 western blots and subsequent densitometry
reﬂected these changes and demonstrated signiﬁcant
reduction of C-CASP2 at 1d and 3d after ONC+ PEDF-34
eye drop treatment compared to ONC+ saline, without
affecting C-CASP3 and C-CASP6 levels (Fig. 4b, c).
Immunohistochemistry also showed that ONC-induced C-
CASP2 immunoreactivity was reduced in βIII-tubulin+
RGC, disappearing at 1d and 3d after ONC+ PEDF-34 eye-
drop treatment (Fig. 4d). Taken together, these results
suggest that eye drops of PEDF-34 suppressed ONC-
induced CASP2 in the eye without affecting other execu-
tioner caspases.
Glia contribute partially to the neuroprotective effects of
PEDF
In mixed retinal cultures, where glial cell proliferation is
inhibited with 5-FDU (Supplementary Fig. 3), siCASP2,
PEDF and PEDF-34 treatment resulted in similar levels of
CASP2 mRNA reduction as observed with mixed adult
retinal cultures alone (Fig. 5a). In addition, the % of βIII-
tubulin+ RGC reduced from 63 ± 4% and 82 ± 5% in
mixed retinal cultures (compare with Figs. 2b) to 48 ± 2%
and 65 ± 5% in 5-FDU-treated mixed retinal cultures
after treatment with PEDF and PEDF-34, respectively
(Fig. 5b).
To conﬁrm these effects, puriﬁed adult RGC cultures
subjected to siCASP2, PEDF and PEDF-34 treatment,
resulted in similar levels of CASP2 mRNA reduction as
observed with mixed adult retinal cultures (Fig. 5c).
The % of βIII-tubulin+ RGC did not differ after
siCASP2 treatment when compared with mixed retinal
Fig. 3 PEDF suppresses CASP2 in vivo. a Fold change in CASP2 mRNA at 7d after ONC+ PBS, ONC+ siCNL and ONC+ siCASP2 and ONC+ PEDF
treatment. b, c Western blot and subsequent densitometry to show that ONC-induced C-CASP2 (p12 fragment) was signiﬁcantly suppressed by
siCASP2 and PEDF treatment (n= 18 retinae/treatment)
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cultures (Fig. 5c). However, the % of βIII-tubulin+ RGC
reduced from 63 ± 4% and 82 ± 5% in mixed retinal
cultures (compare with Fig. 2b) to 46 ± 3% and 64 ± 4%
in puriﬁed RGC cultures after treatment with PEDF
and PEDF-34, respectively (Fig. 5d). Taken together,
these results show that PEDF suppresses CASP2
mRNA in in a glia-independent manner but exerts
some of its neuroprotective effects through trans
effects on glia.
Retinal cells secrete NTFs in response to PEDF treatment
which suppress C-CASP2 levels
Mixed retinal cultures exposed to optimal concentrations
of either PEDF (not shown) or PEDF-34 secreted 85 ± 8,
80 ± 12, 65 ± 11 ng/ml of BDNF, GDNF and NGF, respec-
tively, into the culture medium (Fig. 6a). However, only
baseline levels of CNTF and NT-3 were detected. These
results suggest that mixed retinal cells exposed to PEDF-34
secrete signiﬁcant titres of BDNF, GDNF and NGF.
Fig. 4 PEDF-34 eye-drops suppress CASP2 in retinae. a Fold change in CASP2 mRNA after ONC+ saline and ONC+ PEDF-34 daily eye-drops over
21d. b, c Western blot and subsequent densitometry to show that ONC-induced rise in C-CASP2 (p12 fragment) is signiﬁcantly suppressed at 1d and
3d after injury and treatment, without changes in C-CASP3 or C-CASP6 levels. d Immunohistochemistry to show that ONC-induced localisation of C-
CASP2 (red) in βIII-tubulin+ (green) RGC (arrowheads) after ONC+ saline treatment is suppressed by 1d and 3d after ONC+ PEDF-34 eye-drops. Scale
bar= 50 µm. GCL= ganglion cell layer. (n= 18 retinae/treatment)
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We next determined if the secreted titres of BDNF,
GDNF and NGF in combination can suppress CASP2 levels
and thus account for the effects of PEDF-34 on CASP2.
BDNF, GDNF and NGF in combination suppressed CASP2
mRNA by 45 ± 20% compared to NBA or siCNL-treated
wells, whilst BDNF alone suppressed CASP2 mRNA levels
by 44 ± 15% (Fig. 6b). CNTF had no effect on CASP2
mRNA but siCASP2 and PEDF-34 suppressed CASP2
mRNA levels by 90 ± 4 and 86 ± 5%, respectively, when
compared to NBA or siCNL-treated well. Western blot
(Fig. 6c) and subsequent densitometry (Fig. 6d) conﬁrmed
that: CNTF had no effect on C-CASP2 levels; BDNF, GDNF
and NGF in combination suppressed C-CASP2 levels by
50% and that siCASP2 and PEDF-34 caused the greatest
levels of C-CASP2 suppression. The reduction in C-CASP2
levels by BDNF, GDNF and NGF in combination also led to
similar 50% promotion of RGC survival compared to
siCNL-treated control groups and was also 50% of that
afforded by PEDF-34 treatment alone (Fig. 6e, f).
Taken together, these results suggest that mixed retinal
cells exposed to PEDF-34 secrete signiﬁcant titres of NTF
and that some of the effects of PEDF on
CASP2 suppression and RGC survival may be related to
the combined effects of BDNF, GDNF and NGF.
Fig. 5 Glial cells contribute to some of the RGC neuroprotective properties of PEDF. a Fold change in CASP2 mRNA in 5-FDU-treated cultures
showing no change in CASP2 mRNA after siCASP2 or PEDF treatment compared to cultures with glia. b % of surviving βIII-tubulin+ RGC in 5-FDU
treated cultures in siCASP2 treated cells was unaffected but survival was reduced in the absence of glia. c Fold change in CASP2 mRNA in puriﬁed
RGC cultures showing no change in CASP2 mRNA after siCASP2 or PEDF treatment. d % of surviving βIII-tubulin+ RGC in puriﬁed RGC cultures in
siCASP2 treated cells was unaffected but survival was reduced in the absence of glia (n= 9 wells/treatment)
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Blocking the activity of PEDF with a polyclonal antibody
prevents CAPS2 suppression
We next determine if blocking the activity of PEDF can
prevent its effects on CASP2 mRNA and protein sup-
pression in mixed retinal cultures. In the presence of a
polyclonal antibody to PEDF, neither PEDF nor PEDF-34
peptides were able to suppress CASP2 mRNA (Fig. 7a) or
the levels of C-CASP2 protein (Fig. 7b, c). However, in the
absence of the antibody to PEDF, PEDF-34 peptides
signiﬁcantly suppressed CASP2 mRNA (Fig. 7a) and
C-CASP2 protein levels (Fig. 7b, c). Treatment of wells
with the antibody to PEDF also blocked the neuropro-
tective effect of PEDF and PEDF-34 peptides on RGC
survival, where similar levels of survival as control NBA-
treated wells were observed (Fig. 7d, e). However, in the
absence of the antibody to PEDF, the neuroprotective
effect of PEDF-34 peptide was restored, leading to
the survival of 81 ± 5% of RGC (Fig. 7d, e).
Fig. 6 Treatment of retinal cultures with PEDF and PEDF-34 promotes the secretion of NTF. a ELISA to determine levels of BDNF, CNTF, GDNF,
NGF and NT-3 released into the culture medium. Treatment of retinal cultures with ELISA isolated levels of BDNF, GDNF and NGF or CNTF either alone
or in combination partially suppresses b CASP2 mRNA and C-CASP2 protein c, d by western blot and subsequent densitometry. e Representative
images to demonstrate morphology of βIII-tubulin+ RGC (note: neurite outgrowth occurs in surviving βIII-tubulin+ RGC in wells containing PEDF,
BDNF/GDNF/NGF and CNTF). (n= 9 wells/treatment). Scale bar in f= 20 µm
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These results demonstrate that blocking the activity of
PEDF, prevents its biological effects on CASP2 suppression
and thus RGC neuroprotection.
PEDF suppresses C-CASP2, RAIDD, downstream phospho-
c-Jun and Bim
To explore the mechanism of RGC death by CASP2 and
the effect of CASP2 suppression by PEDF, we investigated
components of the CASP2 activation and neuronal death
pathway (Fig. 8a) in retinal mRNA and protein in the
presence or absence of PEDF-34. We show that the PEDF-
34 not only suppressed CASP2 mRNA (by 50%) but sig-
niﬁcantly suppressed RAIDD (by 80%) but not PIDD, and
downstream Bim (by 77%) (Fig. 8b). Western blot (Fig. 8c)
and subsequent densitometry (Fig. 8d) conﬁrmed sig-
niﬁcant changes in C-CASP2, RAIDD but not PIDD and
downstream Bim, whilst phospho-c-Jun was also sig-
niﬁcantly suppressed by PEDF. Immunohistochemistry
Fig. 7 Antagonism of PEDF-34-mediated CASP2 mRNA and C-CASP2 protein reduction by pre-treatment with a polyclonal antibody to
PEDF. a–c Pre-treatment of PEDF and PEDF-34 with a polyclonal antibody to PEDF fails to reduce CASP2 mRNA (a) and protein levels (b) whilst PEDF
is suppressed in the absence of PEDF polyclonal antibody treatment, as conﬁrmed by densitometry (c). d Pre-treatment with PEDF polyclonal
antibody also suppresses the RGC neuroprotective effects of PEDF and PEDF-34. (n= 9 wells/treatment). e Representative images of the treatments
in d to show morphology of βIII-tubulin+ RGC. Scale bar in e= 20 µm
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for downstream Bim in retinal sections showed CASP2
and Bim+ immunoreactivity in the ganglion cell layer
(arrows), inner plexiform layer, occasional cells in the
inner nuclear layer (INL; arrowheads) and the outer
plexiform layer (Fig. 8e). CASP2+ immunoreactivity was
colocalised with Bim+ immunoreactivity in the ganglion
cell layer corresponding to RGC (Fig. 8f; arrows).
Taken together, these results demonstrate that PEDF
suppresses key components of the CASP2 activation
pathway and thus promotes RGC neuroprotection.
Fig. 8 PEDF suppresses components in the CASP2-dependent apoptotic pathway after ONC in vivo. a CASP2-dependent apoptosis requires
the formation of the PIDDosome (Adapted from24). b PEDF treatment suppresses CASP2, RAIDD but not PIDD and downstream Bim mRNA. c, d PEDF
treatment suppresses C-CASP2, RAIDD, phopho-c-Jun and downstream Bim as detected by western blot and densitometry. e, f
Immunohistochemistry to show changes in Bim protein colocalised to caspase-2 in the ganglion cell layer (GCL), inner plexiform layer (IPL),
occasional cells of the inner nuclear layer (INL) whilst high power views of the GCL showed that Bim and caspase-2 were colocalised to RGC. Scale
bars in e and (f)= 50 µm (n= 18 retinae/treatment)
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Discussion
In retinal cultures, we conﬁrmed that siCASP2 caused >
95% RGC neuroprotection20 and that PEDF and PEDF-34
also exhibited signiﬁcant and similar RGC neuroprotec-
tion as reported by us previously11,12. We also observed
that the pre-optimised doses of PEDF and PEDF-34 in
in vitro and in vivo caused signiﬁcant and speciﬁc
reduction in CASP2 mRNA and protein, without affecting
other executioner caspases, and that this reduction in
CASP2 was RGC neuroprotective. PEDF and PEDF-34
but not PEDF-44 were marginally additive in terms of
CASP2 mRNA suppression when treated alongside sub-
optimal concentrations of siCASP2. In addition, some of
the neuroprotective effects of PEDF were mediated by
trans effects on glia. Blocking the activity of PEDF by pre-
incubation with a polyclonal antibody abolished the
neuroprotective effects of PEDF and PEDF-34 on RGC
survival. We also show that suppression of CASP2 by
PEDF also suppressed RAIDD and downstream phospho-
c-Jun and Bim levels in the pathway to CASP2-dependent
apoptosis in RGC.
We have previously shown that ONC speciﬁcally acti-
vates CASP2 in RGC and suppression of CASP2 with
siCASP2 protected > 95% of RGC for up to 84d11,22,23. We
have also shown that PEDF and PEDF-34 promote sig-
niﬁcant RGC neuroprotection and neurite outgrowth/
axon regeneration in vitro and in vivo11,12. Our present
study suggests that exogenous PEDF may offer RGC
neuroprotection by speciﬁcally reducing CASP2. Exo-
genous PEDF has been shown to downregulate apoptotic
genes such as CASP2, calpain-1 and MAPK-1 after
binding to one or more of the high afﬁnity PEDF recep-
tors, thus stimulating phospholipase A2 activity8,10.
Although these studies were performed using established
cell lines such as in Y79 retinoblastoma cells and retinal
pigment epithelium (RPE) cells8,10, the reduction in
CASP2 after exogenous PEDF addition is in agreement
with our current study in primary RGC in vitro and after
ONC in vivo.
PEDF signalling has not yet been fully elucidated, but
inhibition of both nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and ERK1/2 path-
ways abolished the protective effects of PEDF on RGC
in vitro8,33,34. In addition, PEDF-activated ERK1/2 mod-
ulates kinases, phosphatases, transcription factors and
regulators of apoptosis, suggesting multiple pathway
activation roles for PEDF35,36. For example, the activation
of CASP2 in hippocampal neurons in response to NGF
withdrawal or Aβ1-42 treatment, was shown to be
dependent on the adaptor protein RAIDD but not PIDD
and that both CASP2 and RAIDD were required for
downstream c-Jun activation and Bim induction27,28. Our
results agree with these studies and demonstrate that after
ONC, high levels of RAIDD (but not PIDD), phopho-c-
Jun and Bim were detected which were all suppressed by
PEDF treatment suggesting that RGC undergo CASP2-
dependent apoptosis through the c-Jun and Bim pathway.
Interestingly, treatment of retinal cultures with PEDF
induced the production of high titres of BDNF, GDNF
and NGF but not CNTF and NT3, all of which are RGC
neuroprotective. Although low levels of CNTF were
detected in response to PEDF treatment, CNTF and
BDNF have similar effects on RGC survival after
ONC37,38. BDNF administration promotes the survival of
nearly 100% of RGC for 7 days20 but by 14d after ONC,
only ~45% of RGC remain in BDNF-treated eyes39. Sus-
tained RGC neuroprotection has not been observed with
BDNF since its high afﬁnity receptor, TrKB, is rapidly
downregulated in response to ON injury40–42. In addition,
BDNF diminishes CASP2 but not c-Jun immunoreactivity
and this reduction in CASP2 may account for some of its
neuroprotective effects on RGC. In contrast, PEDF not
only suppressed CASP2 but also RAIDD and downstream
phospho-c-Jun and Bim, suggesting that PEDF may have a
different mode of action compared to BDNF. GDNF is
neuroprotective for RGC survival and axon regeneration
but at 14 days after ONC, only 50% of RGC remained in
GDNF-treated eyes43–47. GDNF gene transfer to axoto-
mized RGC also resulted in RGC survival for 2-4 weeks
with a concomitant decrease in caspase-3 and -948. NGF is
also RGC neuroprotective but at 5 weeks after ON injury,
<4% of RGC survived despite repeated intraocular injec-
tions49. Given the neuroprotective properties of all of
these NTF on RGC, it is conceivable that these NTF work
in concert with PEDF to produce the overall RGC neu-
roprotection observed by us after PEDF treatment.
PEDF is normally expressed in pigment, ciliary, corneal
epithelial cells, Muller cells and in astrocytes and RGC. In
addition, retinal-glia-derived PEDF is increased after
exposure to exogenous PEDF11 and therefore may aug-
ment endogenous levels of PEDF, contributing to the
overall neuroprotective effect of PEDF. PEDF compares
well to other neuroprotective agents such as BDNF,
GDNF, NT-3 and TrkB gene transfer, and to caspase
inhibitors. Like BDNF, PEDF may suppress CASP2,
accounting for RGC neuroprotection. However, some of
the effects of PEDF on RGC neuroprotection were due to
trans effects on glia since 5-FDU treated and puriﬁed
RGC cultures showed reduced levels of RGC neuropro-
tection. It may be that despite constitutive expression of
PEDF in the retina, intravitreal injection or eye drops of
PEDF may stimulate autocrine-induced PEDF production
in RGC, astrocytes and Muller cells21. Therefore, secreted
glia-derived PEDF may also supplement exogenous PEDF
titres to augment RGC neuroprotection. PEDF is also
likely to function both directly and indirectly by sup-
pressing CASP2 activity and as a consequence preserving
glutamine synthetase levels, preventing the accumulation
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of reactive oxygen species and counteracting the detri-
mental effects of gliosis11,50.
The clinical signiﬁcance of this work is that PEDF and
PEDF-34 are not only RGC neuroprotective, but also
promote their axons to regenerate and hence represents a
single molecule that could be beneﬁcial in the ﬁght
against vision loss. In addition, PEDF-34 mimics the
activity of full length PEDF but can be delivered through
eye drops, making it an attractive molecule for therapy
since it reduces the need for intravitreal injections and
thus alleviates pain and the risk of infection. In contrast,
siCASP2 is remarkably neuroprotective but does not
promote RGC axon regeneration and hence may require
additional axon regenerative stimuli such as PEDF.
Despite this observation, siCASP2 is currently in Phase II
and III clinical trials for use in non-arteritic anterior
ischaemic optic neuropathy and acute primary angle
closure glaucoma, respectively.
In conclusion, we conﬁrm our previous reports that
PEDF is RGC neuroprotective and demonstrate that this
neuroprotective effect may be mediated by suppression of
CASP2. These ﬁndings re-afﬁrm the useful role of PEDF
as a potential therapeutic in mediating RGC viability
during the treatment of optic neuropathies in which
RGCs die.
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